All In Biotech

Drug Trial Radar · NCT02973776

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Dec 2016

Primary completion

Feb 2017

Study completion Feb 2017

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Nov 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Vasoconstriction study with LEO 90100

Conditions

  • Psoriasis Vulgaris

Interventions

  • LEO 90100 aerosol foamDrug

  • Dermoval®/Dermovate®Drug

  • DiprosoneDrug

  • EloconDrug

  • LocoidDrug

  • LEO 90100 foam vehicleOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditionsTime frame: 18 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CPCAD

    Nice, Cedex, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.